Differential modulation of glioma metabolism and the tumor microenvironment following dexamethasone and bevacizumab treatment
Neuro-Oncology Advances, 2026
Maise L., Krautwurst F., Surender S., Bae G., Zizmare L., Trampert J., Maric M., Beck S., Tatagiba M., Trautwein C., Becker H., Tabatabai G.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Neurology | Pathophysiology | Tissue Lysate |  Olink Target 96 |
Abstract
Background
Dexamethasone (DEXA) is the routine therapy for tumor- or treatment-associated edema management in glioblastoma, whereas bevacizumab (BEV) is increasingly used as a steroid-sparing alternative. Although both reduce edema, their broader immunometabolic effects remain ill-defined. Here, we examine how DEXA and BEV differentially affect tumor metabolism and microenvironment in patient samples and experimental models.
Methods
We integrated 1H-NMR–based metabolomics of human glioblastoma specimens with mechanistic in vitro studies to compare DEXA and BEV. Microenvironmental modulation by DEXA vs BEV was further investigated in vivo in a syngeneic, immunocompetent orthotopic glioma mouse model by flow cytometry and immunohistochemistry, followed by ex vivo co-culture models.
Results
Tumors from DEXA-treated patients (n = 12) vs steroid-naive controls (n = 18) showed nine significantly altered metabolites, including increased lactate, cystathionine, and 2-hydroxybutyrate, indicating a metabolically accelerated, proliferation-associated state. In an immunocompetent orthotopic glioma model, DEXA reduced intratumoral T cell infiltration and induced cytokine conditions favoring regulatory T cells and myeloid recruitment. In contrast, BEV elicited a coordinated immunostimulatory phenotype: it increased chemotactic cytokines in vitro (e.g. CCL5), decreased intratumoral regulatory T cells (CD4+FOXP3+), enhanced activated, Granzyme B (GzmB) expressing effector T cells (CD4+GzmB+) in vivo, and improved spleenocyte-mediated tumor cell killing ex vivo.
Conclusions
Together, DEXA promotes an immunosuppressive, metabolically active tumor microenvironment, whereas BEV supports immune infiltration and activation. These data, combining tissue-derived metabolomics with functional and mechanistic studies in vitro, ex vivo and in vivo, reveal fundamentally divergent immunometabolic effects of anti-edematous therapies with direct implications in clinical practice, particularly alongside immunotherapy in glioblastoma.